ArticleInflammopharmacology2026
In silico guided design and in vivo evaluation of Diacerein loaded SLNs embedded in situ gels for sustained intra-articular osteoarthritis therapy.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoarthritis (OA) is a multifactorial joint disorder characterized by inflammation, oxidative stress, and progressive cartilage degeneration, for which conventional therapeutic agents remain limited by low bioavailability and systemic side effects.
objectivesThis study aims to integrate in silico guided and experimental nanoparticle-based drug formulations and in vivo analysis targeting the inflammatory genes, proteins, and oxidative markers in OA therapy.
methodsIn silico screening was conducted on ligands based on SwissSimilarity and led to the identification of TNF-α inhibitors. High binding affinity and stability of the complex were verified by Docking studies (AutoDock Vina) and molecular dynamics simulations (Desmond), 100 ns. THA was produced. SLNs with Diacerein (DC-SLNs) were prepared and entrapped into thermosensitive in situ gels (ISG) that were made of THA, poloxamer 407 and poloxamer 188. The formulations were assessed physically and in vitro release dynamics. The efficacy of in vivo drug formulation was determined by osteoarthritis rat model with knee diameter, oxidative and inflammatory markers.
resultsSwiss-similarity screening with Rhein as a reference ligand identified eight structurally similar compounds in the DrugBank database, including Diacerein, Rheinanthrone, Salsalate, and others, with high similarity scores (> 0.7); DC showed the strongest TNF-α binding (- 10.7 kJ/mol). The complex stability was proved by MD simulations (RMSD 2.6 A). In both gels, gelation was appropriate, injectability was excellent, and non-Fickian release occurred. Thermal studies, PXRD, and SEM showed lower crystallinity and a porous structure. Both formulations yielded significant reductions in joint swelling, pro-inflammatory cytokines (TNF-α, IL-6, NF-κB), improved antioxidant activity, and reduced inflammatory and oxidative mediators associated with cartilage degradation, while the DC-SLN@THA-ISG has better therapeutic efficacy than DC@THA-ISG.
conclusionIn silico in vivo studies prove the efficacy of DC-SLN@THA-ISG as a biocompatible and sustained intra-articular formulation in managing osteoarthritis.
Indexed as
Identifiers
42902054What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.